Member Info for Topupme

The question is why are we not already one of the listed trial sign up options if they are so proud of their involvement?

Whilst peer review is an established part of the medical world, what peer who knows enough to review a lung treatment isn’t a bit busy at the moment? Any review that matters is likely from a expert paid by a regulator or pharma company . A peer review is entirely voluntary I believe and is for doctors to share ideas/ close down / agree with others in the name of furthering science. Commercial companies And regulators do not sit waiting for these volunteers. They pay someone. That said should a review come in from an esteemed source I’m sure it would be part of a consideration.

Yep that bothers me as well, we think no noise=NDA and I hope we are right but honestly surprised the RNS with 79% didn’t but SNG On the map with a larger percentage of people.

I have wondered this as well , when you are up scaling manufacturing yourselves you are not really looking for a big partner to come and take over. They need a supply chain and a distribution channel and a large cash backer until they hit break even . It’s not a given that it’s an existing pharma .

Because he said they are parking COPD until Covid journey is done . So there is no next planned step with COPD . Data set being used to boost the phase 2. Safety numbers they effectively doubled the trial size from a safety perspective.

Agreed great news, as ever I’m trying to read more than has been said. When I am out of SNG which will hopefully be a good few significant RNS away , what shares are we all going to buy that provides such promise and generates such interest. This is indeed the share of a lifetime.

Manufacturing partner could suggest there isn’t a big pharma waiting to buy. Interesting choice of words. Suggests SNG are more about finding a drug distribution/ logistics channel , more of a wholesaler . Quite different from being brought out or waiting for licensing cheques in the post.
They will need staff with experience in something other than research

Quite revealing that the only comments on his video are basically why isn’t SNG being administered to people already . Guess a lot came from here but hopefully other people are asking to.
It’s frankly bizarre how silent the world has gone on this after revealing such ground breaking results .

If the COPD prelim was was released early to support Covid do they have to RNS it? Would they be able to add to to the dataset for a regulator only .
Just a thought

Do the regulation bodies for drugs have to report when an application is made?
If so where are SNG’s?

Kenneth
The key point is the data set Classification for the trial has been changed from just phase 2 to pivotal.
This means no phase 3 and this is very good news.

I am by no means an expert and others may provide more input on the next point re dates.
I believe all trial plans have to put nominal dates in .
We may well finish sooner.
However there is no escape from the fact they still haven’t filled the home trial and this is a key part of the pivotal data.
They will RNS when recruitment is complete .
This Covid trial nominal timeline is the formal plan.
COPD trial dataset is still due an RNS soon remember this is why SNG are in business in the first place .
And there is nothing to stop an RNS where a big pharma has done a buyout or partnership offer with conditional prices based on approvals.

To add to my previous post
I know we have a lot of speculation on partnerships and or takeover, but these are very much behind closed doors for those involved.
This post is really about the latest official public reality of how the trial is going. The key news being the trial is now pivotal on phase 2 data .

So we have some board Trial timelines that run into feb next year
The data from home trials is likely to be key in shortening the pivotal study , if the data massively agrees with the result of the hospital trial then it’s fast track to approval.
The downside to this is home recruiting in the U.K. is very slow due to the success of lockdown and quarantine.
So the question would be should SNG find a sponsor in a different country and extend the trial over there? This adds cost and complexity but needs to be weighed up over slow recruiting in the U.K. where we are controlling the virus but at cost to the economy.
Are we likely to need a placing to pay for these feb timelines, I know pi’s won’t like it but have to suck it up. What about ii’s ,
Whilst this info came from a us site , is it safe to say the trial rules are standardised across the international medical community? But approval is done on a regional basis , or to put it another way the regional reg bodies all work with the same results data

Thanks stokey, have looked at that , a very vague but official statement form the court to catch all reasons for lateness, I guess if you were in the us court system day by day we could have a better understanding of how this pans out . Sitting here in the UK it’s all a bit remote. It is hopeful that they haven’t served it yet. It’s difficult to see why you wouldn’t have just hit them with it fast if you know in your heart of hearts someone stole your design

Is there a drop dead date on the serve a claim rules? Ie if it’s not served by time x your claim is void

Christoffer , to be honest I don’t know enough about what the us trial site criteria for updates is, I like what you just said re not needing a US site. I suppose what I was trying to say was this does not mean it’s being trialed in the US.

There are no US trial locations stated on the approval site, they are all UK.

Do we think they are being kicked down the road, establishment making some of the right noise whilst making SNG do more proving even though it plainly works.
Always been a bit of a worry to me that our vaccine obsessed government isn’t interested in treatments once the press cameras are away .

And did Susan answer the phone directly or was the call transferred? Think about your own business and how you protect staff from un solicited calls . Do we think Susan was a gatekeeper or a decision maker? One thing Susan can’t do is tell you the date of an RNS before it actually arrives.

SNG have been suitably vague on detail and we shareholders have made up the rest to firm up a date for our timeframes not the companies .
I’m not that bothered from SNG’s end that there is no news . The bigger issue is the frenzy some people are creating when a date passes that was a bit speculative.
That said as the price per share grows I think there is more duty to inform on progress in a grown up manner . £2 a share is very different from 12p and the reporting to shareholders should move accordingly with it

What if the partner for Covid is not the same for COPD ? That could make for some protracted negotiations.